Echo Therapeutics has received the receipt of notices of issuance (NOI) for two patents covering its Symphony transdermal continuous glucose monitoring (tCGM) system and notices of registration for the trademarks Prelude and Symphony.
These patents join 11 US patents and 28 foreign patents already obtained by Echo Therapeutics.
Echo Therapeutics’ Symphony tCGM System is a non-invasive, wireless, tCGM system and the Prelude SkinPrep System for transdermal drug delivery.
Echo Therapeutics chairman and CEO Patrick Mooney said they have recognized the value that their non-invasive, glucose monitoring technology can provide, and these patents reinforce this belief, further demonstrating the proprietary nature of their technology.